Gilead Sciences (GILD) Profit Margin History

Historical gross, operating and net quarterly profit margin for Gilead Sciences (GILD) over the last 10 years. The current net profit margin for Gilead Sciences as of October 20, 2017 is 42.9%.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $106.054B $30.390B
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.